… These include targeted rehabilitation, novel pharmacotherapies, such as growth factors and
… Lastly, we discuss potential strategies and therapeutic interventions to promote motor tract …

… Other driving forces in AD development, aging, chronic … U94 may provide novel avenues
for intervention in MS patients … are yet approved to target endogenous remyelination in MS …

… in these diseases and highlight recent advances in novel therapeutic strategies targeting
neuronal … mitochondria-targeted therapies that may be beneficial for these age-related NDDs. …

… , and preclinical studies utilizing intervention in the urea cycle … ting possible pathophysiologic
drivers. Burgeoning evidence … from 6 to 18 months of age; and dietary BCAAs content was …

… age, dementia is pathologic and is not a normal part of aging… suggesting that targeting
IAPP may be a novel therapeutic … peptide, IAPP, in driving brain pathology associated with …

… FXR deficiency to age-dependent liver tumorigenesis. … because of early intervention with
bezafibrate before judgement … , mutational signatures, mutated driver genes and copy number …

… Please do not use ILILT when driving. Stop using ILILT when … In this model of practice, it
emphasizes that chronic disease is … aging, health span is related to successful aging. Successful …

… found among age- and sex-matched patients without fatigue. The primary motor cortex (M1),
one of the most important regions for voluntary movement and driving muscle movement, …

… It is now widely known that elderly adults over age 65 are usually the AD patients. Aging
is a … dynamics as a novel target for therapeutic intervention. Neural Regen Res 13:616-623. …

… disease (AD) is a degenerative disease of the central nervous system (CNS) that occurs
primarily in elderly … for designing novel targeting clinical therapeutics that promote Aβ clearance. …